期刊文献+

T_1N_0M_0乳腺癌临床病理特征和预后分析 被引量:4

Clinicopathological characteristics and prognosis of breast cancer T_1N_0M_0
原文传递
导出
摘要 目的:探讨T1N0M0乳腺癌患者的临床病理特征与预后关系。方法:收集2003-01-01-2009-12-31广东省妇幼保健院乳腺病防治中心住院治疗的137例T1N0M0乳腺癌患者的资料,回顾性分析临床病理特征与预后的关系。结果:共收治934例Ⅰ~ⅢA期乳腺癌患者,其中T1N0M0乳腺癌137例,占14.7%。137例T1N0M0乳腺癌患者中有33例(24.1%)为T1mic,42例(30.7%)为T1a^T1b,62例(45.2%)为T1c。肿瘤大小与组织学分级(P=0.001)有关,与年龄(P=0.526)、ER/PR(P=0.371)、HER-2(P=0.624)、手术方式(P=0.479)和术后辅助化疗(P=0.066)无明显相关性。中位随访47个月,5例患者复发转移,其中1例患者死于肝转移,5年无病生存期(disease-free survival,DFS)为96.4%,5年总生存期(overall survival,OS)为99.3%。在单因素分析中,T1N0M0乳腺癌的5年DFS与肿瘤组织学分级(P=0.010)和ER/PR状态(P=0.043)有关,而与年龄(P=0.217)、肿瘤大小(P=0.880)、HER-2状态(P=0.769)、手术方式(P=0.477)和有无化疗(P=0.560)无关;在多因素分析中,仅肿瘤组织学分级是5年DFS的独立影响因素,P=0.045。组织学分级G1、G2和G3患者的5年DFS分别为100.0%、96.3%和84.2%,伴有组织学分级非G3患者的5年DFS(98.3%)优于伴有组织学分级G3(84.2%)的患者,P=0.005;G2(96.3%)和G1(100.0%)患者5年DFS差异无统计学意义,P=0.109。结论:肿瘤组织学分级是T1N0M0乳腺癌的5年DFS独立影响因素,肿瘤组织学分级高的患者预后差。肿瘤组织学分级可为T1N0M0乳腺癌的辅助化疗决策提供参考依据。 OBJECTIVE: To investigate the relationship between clinicopathological characteristics and prognosis of T1N0M0patients with breast cancer. METHODS: Collectting the data of 137 cases of hospitalized TI No Mc, patients with breast cancer between 1st January 2003 and 31st December 2009, and retrospectively analyzing the relationship between the clinieopathological characteristics and prognosis. RESULTS: Totally 934 stage I-ⅢA breast cancer patients cases were treated,and breast cancer T1 No M0 137 cases, accounting for 14. 7 %. In 137 cases, 33 cases (24. 1%) were T1mic, 54 cases(30. 7%) for T1a-T1b ,62 cases(45.2%) were T1c. Tumor size and histological grade (P= 0. 001 ) related with age (P=0. 526) ,the status of ER/PR (P=0. 371) ,HER-2 (P=0. 624) and surgical approach (P=0. 479). There was no significant correlation with adjuvant chemotherapy (P= 0. 066). Median follow-up was 47 months with 5 patients recurrence,one patient died of liver metastases. S-year disease free survival(DFS) was 96.4% ,S-year overall survival(OS) was 99.3%. In univariate analysis,5 years DFS was related to tumor histological grade(P 0. 010) and ER/PR status(P= 0. 043) ,but not related to age (P=0. 217) ,tumor size (P=0. 880) ,HER 2 status (P=0. 769) ,surgical approach (P= 0. 477) and with or without chemotherapy (P=0. 560). In the multivariate analysis,independent factors of 5 years DFS was tumor histological grade(P=0. 045). The 5 years DFS of histological G1 and G2 and G3 were 100.0% and 96.3% and 84.2%. The 5 years DFS of histological G3(84.2%) was worse than that of G1 --G2 (98.3%),P=0. 005 and there wasno difference between G2 (96. 3%) and G1 ( 100. 0 %), P = 0. 109. CONCLUSIONS: Clinical and pathological features of age,tumor size, HER-2 status, surgical approach, with or without chemotherapy may not affect 5 years DFS of breast cancer T1N0M0, histological grade and ER/PR status may influence 5 years DFS of breast cancerT1N0M0. Histological grade are independent prognostic factors of T1N0M0 breast cancer,the higher histological grade was,the poorer prognosis would be. Histological grade provide reference for adjuvant chemotherapy in T1N0M0 breast cancer.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2014年第12期940-944,共5页 Chinese Journal of Cancer Prevention and Treatment
关键词 乳腺肿瘤 小肿瘤 临床病理特征 预后 回顾性研究 breast neoplasms small tumour clinicopathological characteristics prognosis retrospective studies
  • 相关文献

参考文献20

二级参考文献115

  • 1李文萍,王颀,张安秦,许娟,赖日权,张江宇,陈中杨,杨剑敏.乳腺导管内癌及伴微浸润的病理和临床特征[J].中华普通外科杂志,2005,20(4):235-237. 被引量:21
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:167
  • 3张俊峰,陈规划,陆敏强,蔡常洁,杨扬,李华,易慧敏.雷帕霉素诱导人肝癌细胞BEL-7402凋亡中Bcl-2作用研究[J].中华肿瘤防治杂志,2006,13(19):1445-1448. 被引量:8
  • 4张宏武,毕晓峰,宣立学,张保宁.以“乳头溢液”为主诉的22例乳腺癌诊断及病理分析[J].华中科技大学学报(医学版),2007,36(3):407-408. 被引量:1
  • 5王颀.乳腺癌的筛查与诊断技术[M].广州:广东科学技术出版社,2009:102-109.
  • 6World Health Organization. World Health Organization category of tumours: pathology and genetics of tumours of the breast and female genital organs[M]. Lyon: IARC Press, 2003: 10-11.
  • 7Kapenhas-Valdes E, Feldman SM, Boolbol SK. The role of mammary ductoscopy in breast cancer: a review of the literature[J]. Annals of Surgical Oncology, 2008, 15(12) :3350-3360.
  • 8Zografos GC, Zagouri F, Sergentanis TN, et al. Evaluation of pain experienced during breast ductal endoscopy [J]. Surg To day, 2008,38(10) :886-889.
  • 9Kapenhas-Valdes E, Feldman SM, Cohen JM, et al. Mammary duetoscopy for evaluation of nipple discharge[J]. Ann Surg Oncol, 2008,15(10):2720-2727.
  • 10Liu GY, Lu JS, Shen KW, et al. Fiberoptic ductoscopy combined with cytology testing in the patients of spontaneous nipple discharge[J]. Breast Cancer Res Treat, 2008,108: 271-277.

共引文献52

同被引文献54

  • 1王佳玉,徐兵河,田丽军,王燕.乳腺癌肝转移的临床病程与预后分析[J].中华肿瘤杂志,2006,28(8):612-616. 被引量:12
  • 2Taylor C, Shewbridge A, Harris J, et al. Benefits of multidiscipli- nary teamwork in the management of breast cancer [J]. Breast cancer,2013,5:79-85.
  • 3Boughey JC, Dietz J. Providing the best care for patients with breast cancer through use of multidiseiplinary team [J]. Ann Surg Oncol, 2014,21 (10) : 3163-3165.
  • 4Lakhani SR, Ellis IO,Schnitt SJ, et al. WHO classification of tumours of the Ioreast[M].Lyon:IARC Press,2012:33-75.
  • 5Edge SB, Compton CC. The american joint committee on cancer: The 7th edition of the ajcc cancer staging manual and the future oftnm[J]. AnnSurgOneol,2010,17(6):1471-1474.
  • 6Goldhirsch A,Winer EP, Coates AS, et al. Personalizing t he treatment of women with early breast cancer: Highlights of the st gallen interna tional expert consensus on the primary therapy of early breast cancer 2013 [J]. Ann Oncol,2013,24(9) :2206-2223.
  • 7Peto R, Davies C, Godwin J, et al. Comparisons between differ ent polychemotherapy regimens for early breast cancer: Meta-an- alyses of long-term outcome among 100,000 women in 123 ran- domised trials [J]. Lancet,2012,379(9814) :432-444.
  • 8Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies- improving the management of early breast cancer: St gallen in- ternational expert consensus on the primary therapy of early breast cancer 2015 [J]. Ann Oncol,2015 ,26(8) :1533-1546.
  • 9Senkus E, Kyriakides S, Ohno S,et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol,2015,26(Suppl 5):v8 -30.
  • 10Sorlie T, Perou CM, Tibshirani R, et al. Gene expression pat- terns of breast carcinomas distinguish tumor subclasses with clinical implications [J]. Proc Natl Acad Sci U S A, 2001,98 (19) :10869 -10874.

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部